Key Highlights

● Medtronic closed at $88.56 on 9 October 2026.

● Market data consensus target is $102.92, implying about 16 per cent upside.

● The analyst rating consensus is Moderate Buy.

● Mizuho set $115, UBS raised a Buy-rated target from $100 to $110.

Shares of Medtronic (NYSE:MDT), a member of the S&P 500, closed at $88.56 on Friday 9 October 2026. Analyst targets sit well above that level, with the consensus implying upside of about 16 per cent, and ratings lean positive. Recent broker revisions have mostly been upward.

What Is the Latest Analyst Price Target?

Market data shows a consensus target of $102.92 from 28 analysts in the past 12 months, with a range from $83 (Goldman Sachs) to $118 (RBC Capital). Against the $88.56 close, that implies upside of about 16 per cent.

The second data set, using third-party data from 29 analysts, shows a mean of $104.44, a median of $106, a high of $121 and a low of $85, implying about 18 per cent upside on its mean.

What Are Wall Street Analysts Saying?

Market data counts 18 Buy and 10 Hold ratings with no Sells and calls the consensus Moderate Buy. The second data set counts 16 Strong Buy, three Buy and ten Hold, with no Sells, and calls it Buy.

A wave of target changes followed results in early September 2026. Mizuho set $115, UBS raised a Buy-rated target from $100 to $110, and Bank of America from $95 to $110, while TD Cowen reiterated Buy at $110 on 30 September. Truist (Hold) moved from $86 to $99 and Stifel (Hold) from $80 to $95. RBC reiterated Outperform at $118, and Deutsche Bank reiterated Hold at $92. Barclays upgraded the stock to a Hold rating on 7 October.

What Could Help the Stock Reach the Price Target?

Steady beats and double-digit revenue growth could help the shares close the gap to the target.

An upgrade trend, such as Barclays' move this month, and a recovery towards the 52-week high of $106.33 shown by market data would also move the share price towards the consensus target.

What Could Prevent the Stock Reaching the Target?

The shares trade well below that 52-week high. Ten of 28 market data ratings are Hold, and the lowest named target, Goldman Sachs at $83, is only a little below the current price. Medical device companies face pricing pressure from hospitals and payers, regulatory scrutiny, product recalls, competition and currency effects given their global operations.

What Should Investors Watch Next?

Investors may want to follow the next quarterly results and any guidance changes, as well as further broker moves following Barclays' upgrade. It is also worth watching whether the share price recovers towards the levels at which brokers set their September targets.

Medtronic and the Gap to Analyst Targets

Medtronic closed at $88.56 on 9 October 2026, against a market data consensus target of $102.92. Mizuho set $115, UBS raised a Buy-rated target from $100 to $110, and Bank of America from $95 to $110, while TD Cowen reiterated Buy at $110 on 30 September.